Oramed Pharmaceuticals INC Schedule 13D activist filings

Oramed Pharmaceuticals Inc. reports changes in beneficial ownership of Nano Dimension Ltd. ordinary shares, including option and put option transactions.

Oramed Pharmaceuticals has increased its stake in Nano Dimension to 7.2% and publicly declared opposition to the company's proposed transaction with Infinite Epigenetics.

Oramed Pharmaceuticals has filed a Schedule 13D reporting a 49.9% beneficial ownership stake in Lifeward Ltd. following the acquisition of Oratech Pharma and a private placement of convertible notes.

Oramed Pharmaceuticals Inc. has increased its beneficial ownership in Nano Dimension Ltd. to 5.2%, expressing strong dissatisfaction with the issuer's management and strategic direction.

Oramed Pharmaceuticals Inc. and CEO Nadav Kidron have jointly acquired a 5.0% stake in Nano Dimension Ltd., signaling intent to engage with management on strategic and governance matters.

Nadav Kidron, a key figure at Oramed Pharmaceuticals Inc., has increased his beneficial ownership to 7.6% of the company's common stock, primarily through equity grants.

Oramed Pharmaceuticals Inc. and its subsidiary Oramed Ltd. have acquired a 19.99% beneficial ownership in Alpha Tau Medical Ltd. through a $36.9 million share purchase and entered into a strategic investor relations and public relations services agreement.